Anaemia: The safety and efficacy of peginesatide in patients with CKD

Nature Reviews Nephrology

Volumn 9, Issue 4, 2013, Pages 192-193

  Eckardt, Kai Uwe ^a  

^a UNIVERSITY OF ERLANGEN NUREMBERG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

HEMOGLOBIN; NOVEL ERYTHROPOIESIS STIMULATING PROTEIN; PEGINESATIDE; RECOMBINANT ERYTHROPOIETIN;

ANEMIA; CHRONIC KIDNEY DISEASE; DRUG APPROVAL; DRUG EFFICACY; DRUG SAFETY; HEMODIALYSIS; HEMOGLOBIN BLOOD LEVEL; HUMAN; INCIDENCE; PRIORITY JOURNAL; RISK ASSESSMENT; SHORT SURVEY; SUDDEN DEATH; TREATMENT DURATION;

ANEMIA; HEMATINICS; HEMOGLOBINS; HUMANS; PEPTIDES; RENAL INSUFFICIENCY, CHRONIC; RISK FACTORS;

EID: 84875711713     PISSN: 17595061     EISSN: 1759507X     Source Type: Journal    
DOI: 10.1038/nrneph.2013.42     Document Type: Short Survey

References (10)

1. Wrighton, N. C. et al. Small peptides as potent mimetics of the protein hormone erythropoietin. Science 273, 458-464 (1996).
2. Fishbane, S. et al. Peginesatide in patients with anemia undergoing hemodialysis. N. Engl. J. Med. 368, 307-319 (2013).
3. Macdougall, I. C. et al. Peginesatide for anemia in patients with chronic kidney disease not receiving dialysis. N. Engl. J. Med. 368, 320-332 (2013).
4. Stead, R. B. et al. Evaluation of the safety and pharmacodynamics of Hematide, a novel erythropoietin agent, in a phase 1, double-blind, placebo-controlled, dose-escalation study in healthy volunteers. Blood 108, 1830-1834 (2006).
5. Macdougall, I. C. et al. Does-finding study of peginesatide for anemia correction in chronic kidney disease patients. Clin. J. Am. Soc. Nephrol. 6, 2579-2586 (2011).
6. Kidney Disease: Improving Global Outcomes (KDIGO) Anemia Work Group. KDIGO Clinical Practice Guideline for Anemia in Chronic Kidney Disease. Kidney Int. Suppl. 2, 279-335 (2012).
7. Besarab, A. et al. The effects of normal as compared with low hematocrit values in patients with cardiac disease who are receiving hemodialysis and epoetin. N. Engl. J. Med. 339, 584-590 (1998).
8. Singh, A. K. et al. Correction of anemia with epoetin α in chronic kidney disease. N. Engl. J. Med. 355, 2085-2098 (2006).
9. Pfeffer, M. A. et al. A trial of darbepoetin α in type 2 diabetes and chronic kidney disease. N. Engl. J. Med. 361, 2019-2032 (2009).
10. Macdougall, I. C. et al. A peptide-based erythropoietin-receptor agonist for pure red cell aplasia. N. Engl. J. Med. 361, 1848-1855 (2009).